NASDAQ:CLPT ClearPoint Neuro (CLPT) Stock Price, News & Analysis $7.39 -0.17 (-2.25%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$7.33▼$7.6850-Day Range$5.25▼$7.6952-Week Range$4.05▼$7.97Volume92,000 shsAverage Volume174,393 shsMarket Capitalization$202.63 millionP/E RatioN/ADividend YieldN/APrice Target$11.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ClearPoint Neuro alerts: Email Address ClearPoint Neuro MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside53.4% Upside$11.33 Price TargetShort InterestHealthy3.12% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.26Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.63) to ($0.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.54 out of 5 starsMedical Sector523rd out of 936 stocksSurgical & Medical Instruments Industry69th out of 101 stocks 3.5 Analyst's Opinion Consensus RatingClearPoint Neuro has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageClearPoint Neuro has only been the subject of 1 research reports in the past 90 days.Read more about ClearPoint Neuro's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.12% of the outstanding shares of ClearPoint Neuro have been sold short.Short Interest Ratio / Days to CoverClearPoint Neuro has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in ClearPoint Neuro has recently decreased by 37.53%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldClearPoint Neuro does not currently pay a dividend.Dividend GrowthClearPoint Neuro does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLPT. Previous Next 3.5 News and Social Media Coverage News SentimentClearPoint Neuro has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for ClearPoint Neuro this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for CLPT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added ClearPoint Neuro to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ClearPoint Neuro insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.11% of the stock of ClearPoint Neuro is held by insiders.Percentage Held by InstitutionsOnly 30.08% of the stock of ClearPoint Neuro is held by institutions.Read more about ClearPoint Neuro's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ClearPoint Neuro are expected to grow in the coming year, from ($0.63) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ClearPoint Neuro is -8.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ClearPoint Neuro is -8.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClearPoint Neuro has a P/B Ratio of 8.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ClearPoint Neuro's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About ClearPoint Neuro Stock (NASDAQ:CLPT)ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.Read More CLPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLPT Stock News HeadlinesJuly 17, 2024 | globenewswire.comClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024July 17, 2024 | investorplace.com7 Growth Stocks That Could 5X in 5 YearsJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 20, 2024 | globenewswire.comClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical TrialJune 20, 2024 | prnewswire.comParkinson's Disease Clinical Trial Uses Intraoperative MRI to Guide Precision Implantation of Patients' Own Autologous Replacement NeuronsJune 1, 2024 | globenewswire.comClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy SystemMay 8, 2024 | msn.comClearPoint Neuro, Inc. (NASDAQ:CLPT) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comClearPoint Neuro Inc (CLPT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth ...July 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 7, 2024 | finance.yahoo.comClearPoint Neuro Inc. Reports Strong Q1 2024 Performance, Surpassing Revenue ExpectationsMay 7, 2024 | msn.comCLPT Stock Earnings: ClearPoint Neuro Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | finance.yahoo.comClearPoint Neuro Reports First Quarter 2024 ResultsMay 2, 2024 | finance.yahoo.comClearPoint Neuro to Present Novel Research and Exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting in BaltimoreMay 2, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)May 1, 2024 | investorplace.com7 Penny Stocks That Could Make You a Fortune (If You Dare)April 29, 2024 | finance.yahoo.comClearPoint Neuro Announces FDA Clearance of Prism Bone Anchor AccessoryApril 24, 2024 | finance.yahoo.comClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic SystemApril 23, 2024 | finance.yahoo.comClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024See More Headlines Receive CLPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ClearPoint Neuro and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Confirmed)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:CLPT CUSIPN/A CIK1285550 Webwww.clearpointneuro.com Phone(949) 900-6833Fax949-900-6834Employees110Year FoundedN/APrice Target and Rating Average Stock Price Target$11.33 High Stock Price Target$15.00 Low Stock Price Target$9.00 Potential Upside/Downside+53.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,090,000.00 Net Margins-78.84% Pretax Margin-78.84% Return on Equity-76.92% Return on Assets-43.94% Debt Debt-to-Equity RatioN/A Current Ratio3.14 Quick Ratio2.61 Sales & Book Value Annual Sales$26.16 million Price / Sales7.76 Cash FlowN/A Price / Cash FlowN/A Book Value$0.86 per share Price / Book8.60Miscellaneous Outstanding Shares27,420,000Free Float25,745,000Market Cap$202.91 million OptionableOptionable Beta1.07 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Joseph Michael Burnett (Age 47)President, CEO & Director Comp: $803.12kMr. Danilo D'Alessandro (Age 38)Chief Financial Officer Comp: $459.26kMr. Jeremy Stigall (Age 40)Chief Business Officer Comp: $392.66kMr. Mazin Sabra (Age 43)Chief Operating Officer Ms. Ellisa CholapraneeGeneral Counsel & SecretaryMs. Jacqueline KellerVice President of MarketingMore ExecutivesKey CompetitorsPro-DexNASDAQ:PDEXNeuroneticsNASDAQ:STIMApyx MedicalNASDAQ:APYXT2 BiosystemsNASDAQ:TTOODarioHealthNASDAQ:DRIOView All CompetitorsInstitutional OwnershipLegato Capital Management LLCBought 28,227 shares on 7/26/2024Ownership: 0.580%AWM Investment Company Inc.Bought 131,431 shares on 5/16/2024Ownership: 0.479%Price T Rowe Associates Inc. MDBought 1,813 shares on 5/15/2024Ownership: 0.091%CM Management LLCBought 175,000 shares on 5/14/2024Ownership: 1.368%Russell Investments Group Ltd.Bought 46,096 shares on 5/8/2024Ownership: 0.171%View All Institutional Transactions CLPT Stock Analysis - Frequently Asked Questions How have CLPT shares performed this year? ClearPoint Neuro's stock was trading at $6.79 at the start of the year. Since then, CLPT stock has increased by 8.8% and is now trading at $7.39. View the best growth stocks for 2024 here. How were ClearPoint Neuro's earnings last quarter? ClearPoint Neuro, Inc. (NASDAQ:CLPT) issued its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.03. The company earned $7.64 million during the quarter, compared to analysts' expectations of $7.04 million. ClearPoint Neuro had a negative trailing twelve-month return on equity of 76.92% and a negative net margin of 78.84%. Who are ClearPoint Neuro's major shareholders? Top institutional investors of ClearPoint Neuro include Legato Capital Management LLC (0.58%). View institutional ownership trends. How do I buy shares of ClearPoint Neuro? Shares of CLPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CLPT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ClearPoint Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ClearPoint Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
